LeMaitre Vascular (LMAT) Competitors $82.06 +1.29 (+1.60%) As of 02:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LMAT vs. GKOS, BLCO, SLNO, IRTC, INSP, TMDX, NVST, PRCT, WRBY, and LIVNShould you be buying LeMaitre Vascular stock or one of its competitors? The main competitors of LeMaitre Vascular include Glaukos (GKOS), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), iRhythm Technologies (IRTC), Inspire Medical Systems (INSP), TransMedics Group (TMDX), Envista (NVST), PROCEPT BioRobotics (PRCT), Warby Parker (WRBY), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry. LeMaitre Vascular vs. Its Competitors Glaukos Bausch + Lomb Soleno Therapeutics iRhythm Technologies Inspire Medical Systems TransMedics Group Envista PROCEPT BioRobotics Warby Parker LivaNova LeMaitre Vascular (NASDAQ:LMAT) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Do insiders and institutionals hold more shares of LMAT or GKOS? 84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 9.5% of LeMaitre Vascular shares are held by insiders. Comparatively, 5.8% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is LMAT or GKOS more profitable? LeMaitre Vascular has a net margin of 19.96% compared to Glaukos' net margin of -31.40%. LeMaitre Vascular's return on equity of 13.53% beat Glaukos' return on equity.Company Net Margins Return on Equity Return on Assets LeMaitre Vascular19.96% 13.53% 9.78% Glaukos -31.40%-10.66%-8.06% Do analysts rate LMAT or GKOS? LeMaitre Vascular currently has a consensus price target of $97.83, suggesting a potential upside of 19.59%. Glaukos has a consensus price target of $134.67, suggesting a potential upside of 42.76%. Given Glaukos' stronger consensus rating and higher possible upside, analysts plainly believe Glaukos is more favorable than LeMaitre Vascular.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LeMaitre Vascular 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Glaukos 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media prefer LMAT or GKOS? In the previous week, LeMaitre Vascular had 2 more articles in the media than Glaukos. MarketBeat recorded 6 mentions for LeMaitre Vascular and 4 mentions for Glaukos. LeMaitre Vascular's average media sentiment score of 1.17 beat Glaukos' score of 1.05 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, LMAT or GKOS? LeMaitre Vascular has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Which has stronger valuation and earnings, LMAT or GKOS? LeMaitre Vascular has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeMaitre Vascular$219.86M8.41$44.04M$1.9841.32Glaukos$383.48M14.06-$146.37M-$2.37-39.80 SummaryLeMaitre Vascular beats Glaukos on 9 of the 15 factors compared between the two stocks. Get LeMaitre Vascular News Delivered to You Automatically Sign up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LMAT vs. The Competition Export to ExcelMetricLeMaitre VascularMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.85B$10.41B$5.70B$9.52BDividend Yield0.97%2.00%4.60%3.99%P/E Ratio41.3216.9628.0020.01Price / Sales8.4126.79457.41102.39Price / Cash34.4023.2136.5558.97Price / Book5.453.628.595.87Net Income$44.04M$234.77M$3.24B$258.50M7 Day Performance2.55%5.38%3.71%1.95%1 Month Performance-3.24%7.26%10.26%12.31%1 Year Performance-5.14%-14.31%34.07%19.02% LeMaitre Vascular Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LMATLeMaitre Vascular2.6543 of 5 stars$82.06+1.6%$97.83+19.2%-10.6%$1.85B$219.86M41.42490Positive NewsAnalyst ForecastGKOSGlaukos4.3773 of 5 stars$96.97-0.7%$134.67+38.9%-23.0%$5.58B$383.48M-40.92780Positive NewsUpcoming EarningsBLCOBausch + Lomb3.0175 of 5 stars$13.92+0.1%$15.45+11.0%-13.1%$4.92B$4.79B28.9613,500Upcoming EarningsSLNOSoleno Therapeutics3.7624 of 5 stars$86.97-0.3%$108.70+25.0%+82.7%$4.39BN/A-18.8230Positive NewsIRTCiRhythm Technologies1.0589 of 5 stars$135.52-0.5%$137.30+1.3%+35.9%$4.35B$591.84M-43.162,000Upcoming EarningsINSPInspire Medical Systems4.9111 of 5 stars$125.13-1.3%$210.27+68.0%-8.0%$3.74B$802.80M58.451,246Positive NewsAnalyst ForecastTMDXTransMedics Group2.117 of 5 stars$103.61-5.7%$129.88+25.3%-28.4%$3.72B$441.54M80.79210Positive NewsUpcoming EarningsNVSTEnvista3.3406 of 5 stars$19.47-0.2%$20.23+3.9%+26.8%$3.31B$2.51B27.4812,300News CoverageUpcoming EarningsPRCTPROCEPT BioRobotics2.5008 of 5 stars$57.05-2.2%$84.13+47.5%-13.1%$3.23B$224.50M0.00430News CoverageWRBYWarby Parker2.75 of 5 stars$24.35+1.7%$22.88-6.0%+48.4%$2.50B$771.32M0.003,780News CoverageInsider TradeLIVNLivaNova3.3281 of 5 stars$42.35+0.9%$59.29+40.0%-19.5%$2.29B$1.25B-10.352,900Positive News Related Companies and Tools Related Companies GKOS Alternatives BLCO Alternatives SLNO Alternatives IRTC Alternatives INSP Alternatives TMDX Alternatives NVST Alternatives PRCT Alternatives WRBY Alternatives LIVN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LMAT) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LeMaitre Vascular, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LeMaitre Vascular With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.